Skip to main content
Clinical Trials/CTRI/2015/09/006177
CTRI/2015/09/006177
Completed
Phase 2

A clinical study to evaluate efficacy and safety of AHPL/AYTAB/0313 in subjects suffering from osteoarthritis of knee(s) - NI

Ari Healthcare Pvt Ltd0 sites48 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Ari Healthcare Pvt Ltd
Enrollment
48
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Ari Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\.Subject willing to participate, who have read, understood and signed informed consent form
  • 2\.Subject with history of knee pain due to osteoarthritis requiring use of NSAIDs acetaminophen, or another analgesic agent on a regular basis (greater than or equal to 3 days per week) for at least 6 months before the screening visit.
  • 3\.OA confirmed by radiographs and diagnosed according to ACR diagnostic criteria (clinical and radiological) for the OA of the knee.
  • 4\.Subjects are willing to make all required study visits
  • 5\.Subjects are willing to follow study instructions given by the investigator

Exclusion Criteria

  • 1\.Subjects refused to give their informed consent
  • 2\.Subjects with rheumatoid arthritis, gout, pseudo gout, inflammatory arthritis, Pagets disease of bone, chronic pain syndrome, fibromyalgia, or another major joint disease
  • 3\.Subjects with history of surgery, including arthroscopy, or major trauma to the study joint in the previous six months before the screening visit
  • 4\.Subjects requiring knee arthroplasty within 6 months of screening or anticipating any need for a surgical procedure on the index joint during the study
  • 5\.Subjects with signs of clinically important active inflammation of the study knee joint including redness, warmth and or a large, bulging effusion with the loss of normal contour at the screening and or baseline visits
  • 6\.Subjects using systemic corticosteroids within 2 months of screening, or intraarticular visco\-supplementation within the past 3 months
  • 7\.Subjects with any other investigational drug within 1 month prior to randomization;
  • 8\.Subjects having diabetes mellitus, tuberculosis, HIV, ischemic heart disease
  • 9\.Subjects with known major medical or surgical disease
  • 10\.Pregnant and lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials